FMP
Oct 06, 2025(Last modified: Oct 07, 2025)
Constellation Brands Inc (NYSE:STZ), a leading name in the Beverages - Alcohol industry, recently unveiled its fiscal second-quarter earnings for 2026. The company, renowned for owning popular brands like Modelo, outperformed Wall Street's forecasts with an earnings per share (EPS) of $3.63, surpassing the anticipated $3.37. This achievement represents an earnings surprise of 7.72%, as highlighted by Zacks.
Despite the positive earnings surprise, Constellation Brands experienced a year-over-year decline in earnings, dropping from $4.32 per share to $3.63. Revenue for the quarter was $2.48 billion, slightly above the estimated $2.46 billion, but down from $2.92 billion a year ago. This represents a 15% decrease in net sales, partly attributed to challenges such as aluminum tariffs impacting the operating margin, which declined by 200 basis points.
The company reported a net income of $466 million, a significant improvement from the previous year's loss of $1.2 billion. Excluding restructuring costs and other items, the adjusted earnings were $3.63 per share. Despite the challenging socioeconomic environment, Constellation Brands remains committed to its strategic plans, focusing on share and distribution gains.
Following the earnings report, Constellation Brands' stock price saw an approximate 3% increase in extended trading. However, the company reiterated its lowered full-year guidance, citing macroeconomic headwinds as a significant challenge. The report also highlighted a high-single-digit decline in net sales for its beer segment and a double-digit decline in organic net sales for its wine and spirits business.
In terms of financial metrics, Constellation Brands boasts a price-to-sales ratio of approximately 2.43 and an enterprise value to sales ratio of about 3.57. The enterprise value to operating cash flow ratio stands around 11.60, indicating cash flow efficiency. The debt-to-equity ratio is approximately 1.59, suggesting a higher level of debt compared to equity. The current ratio is about 1.07, reflecting the company's ability to cover short-term liabilities with short-term assets.
Abivax (NASDAQ:ABVX) is a prominent biotech company known for its innovative treatments in the field of inflammatory dis...
On October 6, 2025, Lutnick Brandon, a director and 10 percent owner of BGC Group, Inc. (NASDAQ:BGC), purchased 3,946,14...